What DongKwang Pharm does

DongKwang Pharm (동광제약) is a privately held South Korean pharmaceutical manufacturer established in 1952 and headquartered in Seoul, with a KGMP-certified manufacturing plant in Pyeongtaek, Gyeonggi-do. The company develops, manufactures, and distributes approximately 150 prescription pharmaceutical products spanning multiple dosage forms — internal solid formulations (tablets, capsules, powders, granules), penicillin medicines, parenteral injections (cefa/general powder vials, liquid vials, pre-filled syringes, freeze-dried vials, ampoules), ointment/cream/gel products, and liquid medicines. Therapeutic coverage includes anti-inflammatory/analgesics, corticosteroids, antibiotics, dermatologicals, cardiovascular drugs, urological preparations, and respiratory medications, supported by a central R&D center in Seoul conducting formulation, natural substance, and analytical development work. Key brands include ARAGAN (CE-certified osteoarthritis injectable, USD $1M+ cumulative exports to Taiwan) and SILKRON Cream (80 million+ cumulative tubes sold since July 2008).

Name

DongKwang Pharm

Legal name

동광제약 주식회사

Website

https://dkpco.co.kr

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

11–50 employees

Short description

DongKwang Pharm is a privately held Korean pharmaceutical manufacturer founded in 1952 that produces and distributes approximately 150 prescription drugs across multiple therapeutic categories, serving hospitals, clinics, and pharmacies domestically and exporting to 30 countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Prescription pharmaceuticals
• Generic drug manufacturing
• Injectable formulations
• Dermatological products
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical product sales (domestic): Sale of prescription and over-the-counter pharmaceutical products to hospitals, clinics, pharmacies, and hospital wholesale distributors across South Korea through a network of regional branches.
2. International pharmaceutical exports: Export of pharmaceutical products to approximately 30 countries including Vietnam, Taiwan, CIS countries, UAE, Japan, and NATO. Key export products include SILKRON Cream, ARAGAN series, and various injectables.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

DongKwang Pharm manufactures and distributes approximately 150 prescription pharmaceutical products across multiple dosage forms — tablets, capsules, ointments, creams, pre-filled syringes, ampoules, freeze-dried injections, and liquid syrups — for therapeutic areas including anti-inflammatory, corticosteroid, antibiotic, cardiovascular, dermatological, urological, and respiratory conditions. The company sells primarily to Korean hospitals, clinics, hospital wholesalers, and retail pharmacies via a Medical Representative field force, and exports to approximately 30 countries. It also offers contract manufacturing (OEM/CMO) services for other pharmaceutical companies.

Product overview

DongKwang Pharm is a Korean pharmaceutical company established in 1952 that develops, manufactures, and markets prescription drugs across multiple therapeutic categories. The company's product portfolio includes antihypertensives (Teloset, Baroset combinations), corticosteroids (Triamcinolone, Dexamethasone injections), topical dermatologicals (Silkron cream, Endix-G cream), respiratory drugs (Ambroxol injection, Eltine capsules), injectables (Argan, Argan Plus for osteoarthritis), and medications for dyslipidemia, osteoporosis, and other conditions. DongKwang Pharm operates manufacturing facilities in Pyeongtaek producing solid formulations, penicillin products, parenteral injections, ointments, and liquids under KGMP standards, exporting to approximately 30 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• ARAGAN: Brand for injectable products including ARAGAN inj. and ARAGAN PLUS inj., used for treatment of osteoarthritis. Acquired European certification (CE certificate). Exported to Taiwan, UAE, and other markets. Accumulated sales exceeded 1 million USD to Taiwan.

Products and services

• Teloset tablets 40/5/12.5mg (Telmisartan/Amlodipine/Hydrochlorothiazide) Combination antihypertensive prescription medication containing telmisartan, amlodipine, and hydrochlorothiazide for the treatment of hypertension.
• Baroset tablets 10/160/25mg (Amlodipine/Valsartan/Hydrochlorothiazide) Triple combination antihypertensive prescription drug with amlodipine besylate, valsartan, and hydrochlorothiazide for the treatment of hypertension.
• Baroset tablets 10/160/12.5mg and 5/160/12.5mg (Amlodipine/Valsartan) Combination antihypertensive prescription medications with amlodipine and valsartan in two dosage strengths (10/160/12.5mg and 5/160/12.5mg).
• Sugar Cell pre-filled syringe (Sugadex Sodium) Pre-filled syringe formulation of sugadex sodium for parenteral administration.
• AMBROXOL injection Ambroxol hydrochloride injection for chronic respiratory disease and respiratory distress syndrome. Administered I.M., I.V., or S.C. at 15mg 2-3 times daily.
• SILKRON cream Topical cream containing betamethasone dipropionate, clotrimazole, and gentamicin sulfate for allergic dermatitis, contact dermatitis, and atopic dermatitis. Key export product with 80M+ cumulative tubes sold.
• ENDIX-G cream Topical cream containing econazole nitrate, triamcinolone acetonide, and gentamicin sulfate for allergic inflammatory dermatosis, eczema, and tinea infections.
• DEXTASONE injection Dexamethasone disodium phosphate 5mg injection for bronchial asthma, dermatitis, psoriasis, allergic rhinitis, and rheumatic disorders.
• TRIAMCINOLONE injection Corticosteroid injection containing triamcinolone acetonide in 40mg, 50mg, and 200mg formulations for synovitis of osteoarthritis, rheumatoid arthritis, and endocrine disorders.
• VR Tab. Prescription tablet for treatment of hypertension and dyslipidemia.
• Mentine Tab. Prescription tablet for the treatment of severe Alzheimer disease.
• PF Cap. Incrementally Modified Drug (the first of its kind in the world) for dyslipidemia treatment.
• Eltine Cap. Prescription antitussive expectorant medication.
• Tabactam Inj. Prescription injectable antibiotic for treatment of severe infections; exceeded 10 billion KRW annual sales.
• Thy 1 Inj. Prescription injection indicated as adjuvant treatment for flu vaccine.
• Tathione ophthalmic solution 2% Sterile pharmaceutical freeze-drying ophthalmic solution approved by Japan PMDA GMP.
• Esomark Tab. Prescription proton pump inhibitor (PPI) medication for gastrointestinal conditions.
• Sodium Ibandronate Inj. Prescription injectable for the treatment of osteoporosis.
• Dongkwang Limaprost Tab. Prescription tablet for lumbar spinal canal stenosis, with Middle East market release.
• Dongkwang Tamsulosin HCI Prescription medication for prostatic hypertrophy.
• Argan Inj. Injectable prescription product for osteoarthritis treatment; key export product with European CE certification and $1M+ cumulative export sales to Taiwan.
• Argan Plus Inj. Injectable prescription product for treatment of osteoarthritis; exported to UAE with European CE certification.
• Contract Manufacturing Services (OEM/CMO) Contract manufacturing (OEM/CMO) services for other pharmaceutical companies, leveraging DongKwang's KGMP-certified Pyeongtaek plant and multi-dosage form capabilities.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor.

• JS Pharmaceuticals Ltd.minorGTM or Marketing Partner · 1 November 2014Engaged in co-marketing activities for Streptokinase Tab., an anti-inflammatory enzyme preparation.
• Sae Han Pharm Co., Ltd.minorGTM or Marketing Partner · 1 June 2014Engaged in co-marketing for Traumeel Injection, an anti-inflammatory enzyme preparation.
• Daehwa Pharm Co., Ltd.minorGTM or Marketing Partner · 1 June 2014Engaged in co-marketing for ARAGANplus Injection, a medicine for degenerative arthritis.
• European certification bodyminorOthers · 1 July 2012Acquired European CE certification for ARAGAN inj. and ARAGAN PLUS inj., enabling market access in European jurisdictions.

Scale indicators8 records

Recent moves15 records

Expansion highlights6 records

Direct peers

• Boryung Pharmaceutical: Korean pharmaceutical company with a comparable mix of prescription drugs (cardiovascular, anti-infectives, CNS) and nationwide hospital/pharmacy distribution. Boryung is a closely comparable peer in terms of size category, therapeutic coverage, and Korean domestic market focus.
• Daewoong Pharmaceutical: Major Korean pharmaceutical company with strong positions in prescription drugs, injectables, and dermatology. Directly comparable to DongKwang's core business in specialty injectables (e.g., ARAGAN osteoarthritis franchise) and topical dermatology (SILKRON) — both are KGMP manufacturers with nationwide Korean hospital distribution.
• Dong-A Pharmaceutical: Long-established Korean pharmaceutical manufacturer with a comparable heritage business model — branded prescription drugs, OTC products, hospital channel distribution, and selective export presence. Highly comparable to DongKwang in terms of diversified dosage form manufacturing and broad therapeutic coverage.
• Samjin Pharmaceutical: Korean generic pharmaceutical manufacturer with similar mid-sized positioning, KGMP manufacturing, and broad therapeutic category coverage. Samjin and DongKwang are direct peers in the generic and branded-generic hospital channel in Korea.
• Yuhan Corporation: One of Korea's largest domestic pharmaceutical manufacturers with a diversified prescription drug portfolio across multiple therapeutic areas. Directly comparable as a Korean pharma manufacturer with a focus on branded and generic prescription products, hospital sales channels, and export operations — but at significantly larger scale than DongKwang.
• Hanmi Pharmaceutical: Korean specialty pharmaceutical company with significant R&D investment and global licensing partnerships. Comparable in product categories (chronic disease, injectables) and Korean hospital/pharmacy channel, though Hanmi operates at a meaningfully larger scale and with a stronger innovation pipeline than DongKwang.
• Green Cross Corporation: Korean pharmaceutical manufacturer with a comparable broad prescription drug portfolio including injectables, vaccines, and blood products. Similar heritage and KGMP manufacturing footprint, with comparable hospital-channel distribution model and selective export activities.
• JW Pharmaceutical: Mid-sized Korean pharmaceutical company with comparable prescription drug portfolio across multiple therapeutic categories and a similar national sales network. JW and DongKwang occupy similar mid-tier positioning in the Korean pharma market with hospital-channel and selective export exposure.
• Chong Kun Dang Pharmaceutical: Korean pharmaceutical manufacturer with a comparable mid-cap profile, broad prescription drug portfolio, and emphasis on injectables and chronic disease therapies. Operates as a direct domestic competitor to DongKwang in the same hospital and pharmacy channels.

Emerging players

• Kolmar Korea (KolmarBNH): Korean pharmaceutical and health products manufacturer with growing CDMO/CMO capabilities across multiple dosage forms including injectables and topical formulations. Comparable to DongKwang in manufacturing capabilities and Korean CDMO market participation, though with a different mix of own-brand vs. contract manufacturing revenue.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DongKwang Pharm